Early Predictors of Severe Acute Pancreatitis

BACKGROUND One of the main pathogenetic aspects of the severe course of acute pancreatitis (AP) is endothelial dysfunction. Under normal physiological conditions, the endothelium has both anticoagulant and procoagulant properties. However, with the development of AP, endothelial dysfunction often begins as a diffuse activation of coagulation, which further potentiates the progression of the systemic inflammatory response syndrome (SIRS) and thereby complicates the course of AP.  

MATERIAL AND METHODS The present retrospective-prospective study included 78 patients; men — 52 (66.7%), women — 26 (33.3%) with severe AP. The mean age was 51.8±14.2 years. The patients were divided into two groups: the 1st group (n=39), based on a retrospective analysis of the data, included patients in whom the following hemostasis parameters were assessed: activated partial thromboplastin time, international normalized ratio, prothrombin. The second group (n=39) included patients in whom, in addition to the above, the following indicators were evaluated: fibrinogen, D-dimer, antithrombin III, protein C.  

CONCLUSION In the course of this study, it was found that routine methods for assessing the parameters of the hemostasis system, including the determination of only activated partial thromboplastin time, international normalized ratio, prothrombin, are uninformative and do not reflect the severity of the disease. A comprehensive comprehensive study of the coagulation system already in the early stages of the disease indicates an existing tendency to a severe course, which allows anticoagulant therapy to be immediately begun, thereby reducing the number of infectious complications, cases of multiple organ failure, and reducing mortality. 

1. Kolotil’shchikov AA. Vybor sposoba sekvestrektomii v lechenii bol’nykh pankeonekrozom: cand. med. sci. diss. synopsis. Moscow; 2021. (In Russ.) Available at: https://viewer.rusneb.ru/ru/rsl01010970174?page=1&rota te=0&theme=white [Accessed Mar 1, 2022]

2. Baron TH, DiMaio CJ, Wang AY, Morgan KA. American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis. Gastroenterology. 2020;158(1):67–75. PMID:31479658 https:// doi.org/10.1053/j.gastro.2019.07.064

3. Glushkov NI, Safin MG, Lobanov MYu, Pakhmutova YuA, Andrusenko АV, Belskiy II, et al. Optimization of surgical tactics in acute pancreatitis. Herald of the Northwestern State Medical University named after I.I. Mechnikov. 2016;8(2):7–13. (In Russ.).

4. Umapathy C, Raina A, Saligram S, Tang G, Papachristou GI, Rabinovitz M, et al. Natural history after acute necrotizing pancreatitis: a large US tertiary care experience. J Gastrointest Surg. 2016;20(11):1844–1853. PMID: 27619808 https://doi.org/10.1007/s11605-016-3264-2 5. Bendersky VA, Mallipeddi MK, Perez A, Pappas TN. Necrotizing pancreatitis: challenges and solutions. Clin Exp Gastroenterol. 2016;9:345–350. PMID: 27826206 https://doi.org/ 10.2147/CEG.S99824

5. Cimmino G, Cirillo P. Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis. Cardiovasc Diagn Ther. 2018;8(5):581–593. PMID: 30498683 https://doi.org/10.21037/ cdt.2018.10.14

6. Fahey E, Doyle SL. Family Cytokine Regulation of Vascular Permeability and Angiogenesis. Front Immunol. 2019;10:1426. PMID: 31293586 https://doi.org/10.3389/fimmu.2019.01426

7. Mukhopadhyay S, Johnson TA, Duru N, Buzza MS, Pawar NR, Sarkar R, et al. Fibrinolysis and Inflammation in Venous Thrombus Resolution. Front Immunol. 2019;10:1348. PMID: 31258531 https://doi.org/10.3389/ fimmu.2019.01348

8. Sato T, Shibata W, Maeda S. Adhesion molecules and pancreatitis. J Gastroenterol. 2019;54(2):99–107. PMID: 30140950 https://doi.org/ 10.1007/s00535-018-1500-0 10. Wan J, Yang X, He W, Zhu Y, Zhu Y, Zeng H, et al. Serum D-dimer levels at admission for prediction of outcomes in acute pancreatitis. BMC Gastroenterol. 2019;19(1):67. PMID: 31046705 https://doi.org/ 10.1186/ s12876-019-0989-x

9. Kiselev VV, Zhigalova MS, Klychnikova EV. The interaction between the systemic inflammatory response and disorders in the hemostasis system in patients with acute heavy pancreatitis. Hospital Medicine: Science and Practice. 2021;4(1):10–16. (In Russ.) https://doi.org/10.34852/ GM3CVKG.2021.50.48.002

10. Vinnik YS, Dunaevskaya SS, Antufrieva DA. Prospective Research of Hemostasis Disorders in the I Phase of Serious Acute Pancreatitis. Annals of the Russian Academy of Medical Sciences. 2018;73(2):122–129. (In Russ.) https://doi.org/10.15690/vramn906

11. Kiselev VV, Zhigalova M.S, Klychnikova EV. Use of low-molecularweight heparin preparations in patients with acute pancreatitis. Hospital Medicine: Science and Practice. 2021;4(2):9–12. (In Russ.) https://doi. org/10.34852/GM3CVKG.2021.85.75.002

12. Dumnicka P, Maduzia D, Ceranowicz P, Olszanecki R, Drożdż R, Kuśnierz-Cabala B. The Interplay between Inflammation, Coagulation and Endothelial Injury in the Early Phase of Acute Pancreatitis: Clinical Implications. Int J Mol Sci. 2017;18(2):354. https://doi.org/ 10.3390/ ijms18020354

13. Samigulina GR, Spiridonova EA, Roitman EV, Samsonova NN, Klimovich LG, Varnavin OA, et al. Early stage hemostasis differences in survivor and lethal cases with acute necrotizing pancreatitis. Russian Journal of Hematology and Transfusiology. 2016;61(2):92–96. (In Russ.) https://doi. org/10.18821/0234-5730-2016-61-2-92-96

14. Tozlu M, Kayar Y, İnce AT, Baysal B, Şentürk H. Low molecular weight heparin treatment of acute moderate and severe pancreatitis: A randomized, controlled, open-label study. Turk J Gastroenterol. 2019;30(1):81–87. PMID: 30289392 https://doi.org/10.5152/ tjg.2018.18583

15. Qiu Qiu, Li Guo Jun, Liang Tang, Yan Guo, Liang Zhi Wen, Bin Warg, et al. The efficacy of low molecular weight heparin in severe acute pancreatitis: A systematic review and meta-analysis of randomized controlled trials. J Dig Dis. 2019;20:512–522. https://doi.org/10.1111/1751- 2980.12815